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Background: Tuberculosis (TB) is an important cause of morbidity and mortality worldwide. Toll-like-receptors (TLRs)
are important for the recognition of the causative agent Mycobacterium tuberculosis. Negative regulation of TLRs
is necessary to control deleterious inflammatory damage, but could provide a means of immune evasion by
M. tuberculosis as well.
Methods: To obtain insight in the extent of expression of inhibitory regulators of immunity in patients with
active TB, peripheral-blood-mononuclear-cells (PBMCs) and plasma were obtained from 54 TB patients and 29
healthy blood donors from Chittagong, Bangladesh. Bilateral alveolar macrophages were obtained from an infected
versus a contralateral normal lung segment of 9 patients. Statistical analyses were performed using Mann–Whitney U
and Wilcoxon matched pairs testing. Correlations were calculated using the Spearman rho test.
Results: PBMCs harvested from TB patients demonstrated increased mRNA expression of IL-1-receptor-associated-
kinase-M, suppressor-of-cytokine-signalling-3 and Toll-interacting-protein. Flow cytometry revealed enhanced
expression of IL-1-receptor-like-1 (ST2) on lymphocytes. Plasma soluble ST2 was elevated in patients with TB and
correlated with established TB biomarkers, most strongly with soluble interleukin-2 receptor subunit α and
interleukin-8. Alveolar macrophage mRNA expression of negative TLR regulators did not differ between the infected
and contralateral lung side.
Conclusion: These results show enhanced expression of distinct negative regulators of innate immunity in PBMCs of
patients with TB and identify plasma soluble ST2 as a potential novel biomarker for TB disease activity.
Keywords: Innate immunity, Toll-like receptors, Negative regulators of TLR signaling, mycobacterium tuberculosis, Lung
inflammation, BronchoscopyBackground
Mycobacterium tuberculosis (Mtb) remains the leading
bacterial agent causing death in humans in the world
today [1,2]. Estimations suggest that this acid-fast rod
shaped bacillus has infected approximately one third of
the world’s population. In 2012 infection developed into* Correspondence: d.c.blok@amc.uva.nl
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1.3 million deaths worldwide [1,2]. Bangladesh is one of
the most affected countries with 225 new cases per
100,000 inhabitants in 2012 and an overall mortality rate
of 45 per 100,000 [1].
Toll-like receptors (TLRs) comprise a family of pattern
recognition receptors specifically designed to recognize
broadly conserved pathogen associated molecular patterns
expressed by microorganisms [3]. While the especially
thick cell wall of Mtb protects to a certain degree against
host immune detection, it also harbors specific antigens
able to induce a TLR response [4,5]. Mycobacterial cellis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mannoside and lipoarabinomannan have been shown to
activate TLR2 signaling (when heterodimerized with ei-
ther TLR1 or TLR6). In addition, TLR4 is capable of
recognizing the Mtb secreted heat shock protein 60/65,
while TLR9 recognizes unmethylated CpG motifs in
mycobacterial DNA. Studies with genetically altered
mice showed an increased susceptibility to Mtb infec-
tion in the absence of TLR2, TLR9 and possibly TLR4
[4,5]. In accordance, MyD88, an adaptor molecule uti-
lized by most Toll/Interleukin-1 receptor (TIR) domain
containing receptors, proved of particular importance
for host defense against Mtb, although this seems
mainly related to its role in interleukin (IL)-1 signaling
[5,6]. Mycobacterial engagement of phagocyte TLRs
and subsequent recruitment of MyD88 eventually cul-
minates in translocation of NF-κB and a robust proin-
flammatory response. Aberrant TLR signaling may
cause collateral tissue damage and dampening of the in-
flammatory response can help to limit detrimental im-
munopathological changes. Several negative regulators
of innate immunity and TLR signaling have been iden-
tified, including cell-surface receptors, such as IL-1
receptor-like 1 (ST2) and single immunoglobulin IL-
1R-related molecule (SIGIRR, TIR8), and intracellular
inhibitors, such as Toll-interacting protein (TOLLIP),
suppressor-of-cytokine signaling (SOCS) and IL-1 re-
ceptor associated kinase (IRAK)-M [7].
Several earlier studies reported on the expression of
TLRs by blood leukocytes in patients with TB [8-11].
We here sought to determine expression of inhibitory
regulators of innate immunity in the circulation and at
the primary site of infection in patients with lung TB. In
addition, we evaluated the value of soluble (s)ST2, a se-
creted protein produced by the st2 gene [12], as a poten-
tial biomarker in TB.
Methods
Study design and population
Patients and healthy blood donors were recruited pro-
spectively in the Tuberculosis Clinic of Chittagong
General Hospital and the Chittagong Medical College
& Hospital, Chittagong, Bangladesh. TB suspicion was
based on the WHO-based National Guidelines for
Bangladesh [13]. Two patient groups were studied. For
the first group, from which only blood was drawn, in-
clusion criteria were: (a) 18–80 years of age; (b) confirmed
pulmonary TB; (c) ability to give written informed consent
prior to study-specific procedures. Exclusion criteria were:
(a) a concomitant disease or a known clinical condition
which could interfere with the conduct of the study; or (b)
an unwillingness or inability to comply with the study
protocol for any other reason. On-site TB confirmation
was defined by a minimum of two out of three positiveZiehl-Neelsen (ZN)-stained sputum samples collected on
two consecutive days. Subsequent confirmation of Mtb
infection was obtained by PCR (GeneXpert, Cepheid,
Solna, Sweden) in the Laboratory of Medical Microbiol-
ogy in the Academic Medical Center (Amsterdam, the
Netherlands) for all but two patients in which PCRs
could not be performed due to technical difficulties.
Healthy blood donors served as controls.
For the second patient group, in which diagnostic
bronchoscopies were performed, inclusion criteria com-
prised: (a) 18–65 years of age; (b) clinical suspicion of
pulmonary TB, according to the WHO-based National
Guidelines for Bangladesh [13], (c) three consecutive ZN
stained sputum samples negative for Mtb; (d) unilateral
abnormalities on chest X-ray suspect for TB; (e) no TB
treatment; (f ) ability to give written informed consent
prior to any study-specific procedure. Blood samples
were taken directly at presentation followed by a bilat-
eral bronchoalveolar lavage to obtain BAL fluid and BAL
cells. Mtb infection was confirmed on site by a ZN-
positive BAL stain or in Amsterdam by PCR. Prior to
bronchoscopy the exact location of the diseased lung
subsegment was identified by chest X-ray. Bilateral BALs
were performed by qualified pulmonologists in a stan-
dardized fashion according to the guidelines of the
American Thoracic Society, using a flexible direct bron-
choscope (Olympus type C30C, P20D and P40, Shinjuku,
Tokyo, Japan). Eight successive 20-mL aliquots of sterile
saline 0.9% were instilled at the uninfected side in a sub-
segment of the middle lobe or lingula and aspirated
immediately with low suction. This was followed by instil-
lation and aspiration of the same amount of aliquots in
the contralateral, diseased lung subsegment. Bronchosco-
pies were not performed in patients with ZN-positive spu-
tum, since these would not contribute to the diagnosis
and patient management.
All patients were tested for human immunodeficiency
virus (HIV) infection by a Determine® HIV 1/2 test (Alere,
Tilburg, The Netherlands). The study was approved by the
National Research Ethics Committee (NREC), Bangladesh
Medical Research Council, Bangladesh and the Oxford
Tropical Research Ethics Committee, University of
Oxford, Oxford, UK (OXTREC 35–09). Written in-
formed consent was obtained from all study subjects or
next-of-kin by a native Bengali speaker.
Sample handling
Blood samples for plasma collection (EDTA and hepa-
rinized blood) and peripheral blood mononuclear cell
(PBMC) harvesting (Cell Preparation Tubes (CPT),
Becton Dickinson, Franklin Lakes, NJ) were taken dir-
ectly at presentation. PBMCs were isolated according to
the manufacturer’s instructions and preserved in RA1
lysis buffer for later RNA extraction (Nucleospin RNA





















Irak-m: Interleukin (IL)-1 receptor (R) associated kinase-m, Sigirr: single
immunoglobulin IL-1 related receptor (molecule), Tir8: Toll/IL-1R 8, Tollip: Toll
interacting protein, IL1RL1: IL-1R like-1, MKP-1: Map kinase phosphatase-1,
Socs: suppressor of cytokine signaling.
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zen (see flow cytometry) awaiting additional analysis.
Alveolar macrophages (AMs) were isolated from BAL
fluid using CD71 MACS beads (Miltenyi Biotec, Bergisch
Gladbach, Germany) as described [14]. In brief, BAL fluid
was centrifuged and cells were resuspended in ice-cold
sterile automated magnetic cell sorting and separation
(autoMACS) buffer (PBS, 0.5% bovine serum albumin,
2 mM EDTA; pH= 7.4). Subsequently, cells were incu-
bated for 15 min with CD71 microbeads at 4°C. Cells were
washed again in autoMACS buffer and purified by auto-
MACS (Multenyi Biotec). The average AM purity was
96% as determined on cytospins. AMs were preserved in
RA1 lysis buffer for RNA analysis (Nucleospin RNA kit,
Macherey-Nagel, Dueren, Germany).
Assays
Levels of the following cytokines, chemokines and other
inflammatory markers were measured in EDTA-plasma
by multiplex assay (Luminex, Austin, TX) using reagents
from Bio-Rad (Veenendaal, the Netherlands): interleukin
(IL)-6, chemokine (C-X-C motif ) ligand (CXCL) 8 (IL-
8), soluble IL-2 receptor subunit-α (sIL-2Rα), soluble
intercellular adhesion molecule 1 (sICAM-1), soluble
TNF receptor-1 and −2 (sTNFR-1, sTNFR-2). IL-33 and
sST2 were measured by specific enzyme-linked immuno-
sorbent assays (R&D systems, Abingdon, UK). C-reactive
protein (CRP) was measured in heparinized plasma sam-
ples with the C-Reactive Protein Gen.3 test kit (Roche
Diagnostics, Mannheim, Germany), an immunoturbidi-
metric method, on the Hitachi Modular P-800 module
(Hitachi, Hitachinaka, Japan).
Flow cytometry
Freshly obtained PBMCs were frozen in RPMI medium
with 20% FCS and 20% DMSO with the help of a ‘mr.
Frosty’ freezing container (Thermo Scientific, Waltham,
US) first placed overnight in a −20° freezer and subse-
quently stored in the gas phase of a liquid nitrogen con-
tainer. Prior to analysis stored cells were carefully
thawed, washed and stained with the following antibodies:
CD14-APC-Cy7, CD3-Alexa Fluor 700, CD4-PERCP-
Cy5.5 or CD4-PE (all BD Biosciences), CD8-PE-Cy7
(eBioscience), ST2-FITC (Acris, Herford, Germany) and
SIGIRR-APC (R&D Systems) for 30 minutes at 4°C. To
stain for TOLLIP cells were permeabilized with perm I
buffer (BD Biosciences) for 20 minutes at 4°C. Perme-
abilized cells were stained intracellularly with antibodies
against TOLLIP (SouthernBiotech, Birmingham, AL)
for 30 minutes at 4°C followed by staining with a
secondary anti-mouse-Alexa Fluor 610-R-Phycoerythrin
(Life technologies, Carlsbad, CA) antibody for 30 -
minutes at 4°C. Data acquisition was performed using a
FACS Canto II (BD biosciences) flow cytometer. Measuredgeomean fluorescence intensities (MFIs) were corrected
with the help of the fitting fluorescence minus one (FMO)
measurements. For cytometric analysis 17 (healthy donor)
versus 19 (TB patient) were compared.
Evaluation of mRNA levels by quantitative RT-PCR
Total RNA obtained from PBMCs and AMs was reverse
transcribed using oligo(dT) primer and moloney murine
leukemia virus reverse transcriptase (Promega, Madison,
WI, USA) according to recommendations of the sup-
pliers. RT-PCRs were performed using FastStart DNA
Master SYBR Green I in a Light Cycler apparatus
(Roche Applied Science, Penzberg, Germany). Primers
used are indicated in Table 1. Quantitative PCR data
were analyzed with the LinRegPCR program [15,16].
All samples were normalized to the house keeping gene
β2-microglobulin [17,18].
Statistical analysis
Data are expressed as dot plots with medians (figures)
or medians with interquartile ranges (tables). Compari-
sons between groups were performed using the Mann–
Whitney U test. Comparisons between paired samples
were performed using a Wilcoxon matched pairs test.
Analyses were done using Graphpad Prism version 5.01
(San Diego, CA). Correlations were calculated using the
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P-values < 0.05 were considered statistically significant.
Results
Patient characteristics
Two patient groups with lung TB were studied. The first
group, from which plasma and PBMCs were obtained,
consisted of 54 patients with primary TB, who were
compared with 29 healthy blood donors. The second
group, consisting of patients suspected to have lung TB
but with ZN negative sputum, comprised 23 patients, 9
of whom were confirmed to have TB by Mtb specific
PCR on BAL material. Patient characteristics and clinical
features are summarized in Table 2.
Expression of cell-surface negative regulators of innate
immunity and plasma sST2 concentrations in patients
with active TB
ST2 and SIGIRR are cell-surface associated receptors
that have been shown to inhibit TLR signaling [19,20].
ST2 mRNA levels were low in PBMCs of both TB pa-
tients and healthy controls and not different between
groups (Figure 1A). Flow cytometry revealed an upregula-
tion of ST2 expression on CD4 and CD8 positive lympho-
cytes, but not on CD14 positive monocytes, of TB patients
when compared to healthy controls (Figure 1B,C). PatientsTable 2 Patient characteristics
Systemic host response
Healthy controls n = 29 Prim
Demographics
Age (years) 31 (26–35) 28 (
Male sex (n, %) 21 (72%) 40 (
Smoker (n, %) 8 (28%) 27 (
HIV-positive (n, %) 0 (0%) 1 (2
Symptoms
Fever (n, %) 0 (0%) 54 (
Night sweats (n, %) 0 (0%) 21 (
Weight loss (n, %) 0 (0%) 39 (
Fatigue (n, %) 1 (3%) 29 (
Shortness of breath (n, %) 0 (0%) 6 (1
Productive cough (n, %) 2 (7%) 50 (
Signs
Temperature (°C) 36.9 (36.5-37.1) 37.4
MAP (mmHg) 83.3 (80–93.3) 80 (
Heart rate (bpm) 80 (78–84) 90 (
Respiratory rate (brpm) 20 (20–24) 25 (
BMI (w/l2) 24 (22.4-25.7) 17.7
Abbreviations: TB tuberculosis, n number of patients, MAP mean arterial blood pres
expressed as weight (w) divided by length (l)2. Percentages given are within study
test: *P < 0.05, **P < 0.01, ***P < 0.001 when compared to healthy controls.with lung TB showed elevated plasma levels of sST2 (261
[183–430] pg/ml; median [IQR]) relative to healthy con-
trols (124 [99–177] pg/ml; P < 0.001) (Figure 1D). In con-
trast, the plasma levels of the ST2 ligand IL-33 were
below or just above the detection limit in both patients
and controls and not different between groups (data not
shown). We next investigated whether plasma sST2 levels
correlated with the plasma concentrations of established
biomarkers of TB. For this we measured IL-6, IL-8 and
IP-10 (which are elevated in active TB), as well as sIL-2Rα,
sICAM-1, sTNFR-1, sTNFR-2 and CRP (which correlate
with the extent of disease in TB) [21] in plasma of TB
patients and healthy controls (Table 3). As expected [21],
the plasma levels of all biomarkers were elevated in TB
patients (all P < 0.001 versus controls). Plasma sST2 corre-
lated significantly with the plasma levels of these TB
biomarkers, although correlations were relatively modest
(Table 4). The strongest correlations were found with
plasma sIL-2Rα (r = 0.52, P < 0.001) and IL-8 (r = 0.50,
P < 0.001).
To obtain insight in (s)ST2 expression at the site of
the infection, we performed bilateral BAL in 9 patients
with confirmed TB and harvested AMs from the site of
infection (as determined by chest X ray) and from the
contralateral lung (not showing a radiologic infiltrate).
sST2 was not detectable in BAL fluid of patients withLocal host response
















sure, bpm beats per minute, brpm breaths per minute, BMI body mass index,
groups. Data presented are medians with interquartile ranges. Mann Whitney-U
Figure 1 ST2 during active pulmonary tuberculosis. (A) ST2 mRNA in PBMCs; (B) ST2 surface expression measured on CD4 and CD8 positive
lymphocytes and CD14 positive monocytes (representative histograms). FMO, fluorescence minus one. (C) Idem for individual subjects (geomean
channel fluorescence intensity (MFI)). (D) Plasma sST2 concentrations. (E) ST2 mRNA in alveolar macrophages (AM) of TB patients originating from
the TB infected lung (open squares) or contralateral lung (closed squares). Depicted mRNA levels are normalized to the house keeping gene
β2-microglobulin. Depicted are dot plots with medians; open dots: TB patients, closed dots: healthy donors. ***P < 0.001.
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AMs from the infected side and the contralateral lung
(Figure 1E).
SIGIRR mRNA levels did not differ in PBMCs from
patients and controls (Figure 2A). In addition, flow cy-
tometry showed similar expression levels in CD4 positive
and CD8 positive lymphocytes, and on CD14 positiveTable 3 Parameters of systemic inflammation during
pulmonary TB
Controls n = 29 TB n = 54
IL-6 (pg/mL) 0.3 (0.06-0.7) 5.8 (3.3-12)***
IL-8 (pg/mL) 0.8 (0.4-1.4) 2.2 (1.3-3.7)***
IP-10 (ng/mL) 0.37 (0.3-0.46) 2.8 (1.6-3.7)***
sIL-2Rα (pg/mL) 74 (54–101) 225 (152–349)***
sICAM-1 (ng/mL) 170 (145–214) 344 (279–418)***
sTNFR-1 (ng/mL) 0.9 (0.7-1.0) 1.7 (1.1-2.0)***
sTNFR-2 (ng/mL) 5.1 (4.6-6.0) 10 (7.8-13)***
CRP (μg/mL) 0.9 (0.3-2.6) 51 (23–90)***
Abbreviations: IL interleukin; IP-10 Interferon gamma-induced protein (CXCL)
10; sIL-2Rα soluble interleukin-2 receptor α; sICAM-1 soluble intercellular adhesion
molecule-1; sTNFR-1,-2 soluble tumour necrosis factor receptor-1 and −2; sST2
soluble ST2 (IL1R like 1); CRP C-reactive protein. Data are medians with
interquartile ranges. ***P < 0.001 for the difference between primary TB versus
controls. Depicted are medians with interquartile ranges.monocytes (Figure 2B,C). SIGIRR mRNA levels did not
differ in AMs from the infected side and the contralat-
eral lung (Figure 2D). Overall these data indicate that
SIGIRR expression is not altered during TB.Expression of intracellular negative regulators of innate
immunity in patients with active TB
We next sought to determine the expression of intracel-
lular negative regulators of innate immunity in the blood
compartment of TB patients (Figure 3). TB patients
showed higher levels of mRNAs encoding IRAK-M
(P <0.01 versus controls), TOLLIP (P <0.05) and SOCS-
3 (P <0.01), whereas the levels of mRNAs encoding A20
and mitogen-activated protein kinase phosphatase
(MKP)-1) did not differ between groups. SOCS-1 mRNA
could not be detected in PBMCs of either TB patients or
controls. The extent of IRAK-M, TOLLIP or SOCS-3
mRNA expression did not correlate with the plasma
concentrations of CRP, IL-6, IL-8, IP-10, sIL-2Rα,
sICAM-1, sTNFR1 or sTNFR2 (data not shown). Flow
cytometry showed no difference in TOLLIP expression
between PBMCs from TB patients and healthy controls.
mRNA levels of IRAK-M, MKP-1, A20 or TOLLIP did
not differ in AMs from the infected site and the
Table 4 Correlations of sST2 with TB biomarkers in patients with primary lung TB
CRP IL-6 IL-8 IP-10 sIL-2Rα sICAM-1 sTNFR-1 sTNFR-2
sST2 rs 0.32 0.33 0.50 0.43 0.52 0.43 0.37 0.39
P 0.02 0.02 <0.001 0.001 <0.001 0.001 0.006 0.004
Abbreviations: IL interleukin; IP-10 Interferon-γ induced protein (CXCL-10); sIL-2R soluble interleukin-2 receptor; sICAM soluble intercellular adhesion molecule;
sTNFR soluble tumour necrosis factor receptor; CRP C-reactive protein; rs Spearman rank coefficient of correlation adjusted for multiple comparisons using
Bonferroni’s procedure.
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could not be detected in AMs.
Discussion
TLRs are important players in the recognition of myco-
bacterial pathogens and the facilitation of the antimicro-
bial immune response [4,5]. Negative regulators of TLR
signaling dampen TLR induced inflammation [7], which
on the one hand can prevent detrimental pathological
changes but on the other hand can provide a pathway
for Mtb immune evasion. Here we sought to obtain
insight in the expression of negative innate immunity
and TLR regulators in the blood compartment and at
the site of infection in patients with TB from an endemic
region in Bangladesh. We showed differential expression
of several inhibitory regulators of innate immunity at ei-
ther mRNA or protein level between patients with activeFigure 2 SIGIRR during active pulmonary tuberculosis. (A) SIGIRR mRN
positive lymphocytes and CD14 positive monocytes (representative histogr
(mean channel fluorescence intensity, MFI). (D) SIGIRR mRNA in alveolar m
(open squares) or contralateral lung (closed squares). Depicted mRNAs are
dot plots with medians; open dots: TB patients, closed dots: healthy donorTB and healthy controls and identified plasma sST2 as a
potential novel biomarker for TB, correlating with estab-
lished biomarkers of TB disease activity.
Many previous studies examined the role of TLRs in
TB. Among the TLR family, TLR2, TLR4 and TLR9 have
been implicated in host defense against Mtb, although
the impact of deficiency of either one of these receptors
was modest or variable in mouse TB models [5,6].
Certain gene polymorphisms in TLRs and related genes
(i.e., TLR1 [22], TLR2 [23-25], and MyD88-adaptor-like
(MAL) [25,26]) have been associated with susceptibility
to TB in humans, suggesting that TLR signaling influ-
ences TB development in the human host. Patients with
active pulmonary TB showed increased TLR1, 2, 4 and 6
mRNA levels in whole blood leukocytes when compared
with healthy controls, while TLR 7 and 9 mRNA expres-
sion was unaltered [9].A in PBMCs. (B) SIGIRR surface expression measured on CD4 and CD8
ams). FMO, fluorescence minus one. (C) Idem for individual subjects
acrophages (AM) of TB patients originating from the TB infected lung
normalized to the house keeping gene β2-microglobulin. Depicted are
s.
Figure 3 Intracellular negative regulators and mediators of TLR signaling. mRNA levels in PBMCs of TB patients (open dots) and healthy
controls (closed dots) and TB patient AMs from the diseased (TB-positive) lung segment (open squares) and from the matching contralateral lung
(closed squares). PBMC mRNA expression of IRAK-M (A), MKP-1 (C), SOCS-3 (E), TOLLIP (F) and A20 (I). AM mRNA expression of IRAK-M (B), MKP-1
(D), TOLLIP (G) and A20 (J). TOLLIP (H) expression levels in CD4 or CD8 positive lymphocytes and CD14 positive monocytes, as determined by
flow cytometry (mean channel fluorescence intensity, MFI). mRNA expression is normalized to β2-microglobulin. Depicted are dot plots with medians;
open dots: TB patients, closed dots: healthy donors. *P < 0.05, **P < 0.01.
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gether with IL-1R accessory protein, functions as the IL-
33 receptor [27]. In addition, a sST2 variant exists which
can act as a decoy receptor for IL-33 [12]. We here de-
tected elevated levels of sST2 in plasma of TB patients.
Elevated circulating sST2 levels have been reported in
different human disease settings, including auto-immune
diseases like systemic lupus erythematosus and rheuma-
toid arthritis [28], asthma exacerbations [29] and cardio-
vascular disease [30]. Our laboratory previously reported
elevated sST2 levels in sepsis [31] and leptospirosis [32].
Hence, elevated sST2 plasma levels by no means are
specific for TB. Rather, circulating sST2 levels could be a
marker for disease activity in TB patients, also consider-
ing the statistically significant correlations between sST2
and known TB biomarkers [21]. Clearly, the potential
value of sST2 as a TB biomarker and its response to TB
treatment need to be tested further in independent co-
horts. We only detected very low amounts of ST2
mRNA in PBMCs of patients with TB. In accordance,
our laboratory previously reported a marked rise in
plasma sST2 concentrations after intravenous adminis-
tration of LPS to healthy humans in the absence of an
increase in ST2 mRNA levels in blood leukocytes [17].
We also found equally low ST2 mRNA levels in AMs
from lungs of TB patients. In agreement, Oshikawa et al.
tested different lung macrophages for ST2 expression
(human and murine cell-lines, and primary human
AMs) and found low or undetectable mRNA levels un-
less cells had been exposed to LPS, IL-1β, TNF-α or IL-6
[29]. Importantly, our group previously documented that
stimulation of whole blood with LPS or viable Leptospira
does not result in sST2 release [32]. Together these re-
sults indicate that plasma sST2 originates from cells not
present in blood. Interestingly, we found increased ST2
surface expression on blood lymphocytes of TB patients,
although ST2 expression was low relative to that on
monocytes. Of note, ST2 deficiency did not influence
mycobacterial loads or disease outcome during murine
Mtb infection [33]. Plasma IL-33 was not elevated in pa-
tients with TB. In accordance, children with TB showed
unaltered circulating IL-33 levels [34].
SOCSs are a family of intracellular proteins function-
ing as feedback inhibitors of cytokine receptors. They
are induced by TLR activation and either directly
(SOCS-1) or indirectly (SOCS-3) interfere with TLR sig-
naling [35]. While we could not detect SOCS-1 mRNA
in PBMCs, confirming a previous report from our group
[17], we report increased mRNA expression of SOCS-3
in PBMCs from pulmonary TB patients when compared
to PBMCs from healthy controls. In contrast, Masood
et al. reported increased SOCS-1 mRNA expression in
PBMCs from patients with advanced lung TB in the ab-
sence of changes in SOCS-3 mRNA expression [36,37].In accordance with our current data, SOCS-3 mRNA
expression was reported increased in whole blood leuko-
cytes [38]. Another investigation demonstrated enhanced
mRNA SOCS-1 and SOCS-3 mRNA levels in induced
sputum from TB patients [8]. We were not able to detect
either SOCS-1 or −3 mRNA in AMs from TB patients
suggesting that SOCS-1 and −3 expression in induced
sputum might originate from a different cell type. A re-
cent study has established the important functional role
for SOCS-3 expression in either lymphoid or myeloid cells
for resistance against Mtb in mice [39].
To the best of our knowledge our study is the first to
report increased IRAK-M mRNA expression in PBMCs
from TB patients. It has been suggested that Mtb
lipoarabinomannan can induce IRAK-M in macro-
phages, thereby attenuating pro-inflammatory signals
[40]. Indeed, IRAK-M mRNA expression was upregu-
lated in induced sputum from TB patients [8]. We did
not find increased IRAK-M mRNA levels in AMs from
TB patients. Of note, however, control AMs were ob-
tained from the contralateral lung of the same patient.
Although patients were selected for one sided radio-
graphic abnormalities and although the contralateral
BAL fluids tested PCR negative for Mtb, one cannot
rule out a spillover effect from the affected to the
contralateral lung. Furthermore, ethical considerations
prevented us from recruiting sputum smear positive pa-
tients for BAL procedure, meaning that bacterial loads
in these patients were low enough to escape repetitive
sputum smear testing (in contrast to the pulmonary TB
patients recruited for PBMC analysis). Therefore, it is
possible that in patients with more extensive pulmon-
ary TB, gene expression is altered in AMs harvested
from the site of infection.
In addition to elevated SOCS-3 and IRAK-M mRNA
levels we observed slightly enhanced expression of
mRNA encoding TOLLIP in PBMCs of TB patients,
which, however, was not accompanied by enhanced
protein expression. In resting cells TOLLIP forms a
complex with either IRAK-1 or −2 thereby preventing
IRAK (auto)phosphorylation and inhibiting IL-1R, TLR2
and TLR4 signaling pathways [41,42]. In accordance, hu-
man peripheral blood monocytes in which TOLLIP was
partially silenced produced more TNFα and IL-6 upon
stimulation withMtb whole cell lysates [43]. Although this
might suggest that TOLLIP may hamper the antimycobac-
terial immune response, SNPs in the human tollip gene
resulting in deficiency are associated with an increased
susceptibility to TB [43]. As such, the functional role of
TOLLIP in TB has yet to be determined. Notably, the ex-
tent of TOLLIP (and IRAK-M) mRNA expression in
PBMCs did not correlate with circulating levels of proin-
flammatory cytokines. This does not contradict the as-
sumption that the enhanced expression of negative innate
Blok et al. BMC Infectious Diseases  (2015) 15:98 Page 9 of 10immunity regulators serves to inhibit aberrant inflamma-
tion caused by activation of immune enhancing receptors
such as TLRs. Rather, it is the balance between pro- and
anti-inflammatory regulators that determines the net ef-
fect on proinflammatory cytokine release.
MKP-1 inactivates MAPKs (in particular p38 and JNK)
which are downstream of TLR signal transduction path-
ways [44]. Silencing of MKP-1 in human blood mono-
cytes decreased phospho-MAPK expression and TNF-α
production in response to BCG, suggestive for a possible
detrimental role of MKP-1 in host defense against Mtb
[45]. We here did not find an effect of active TB on
MKP-1 mRNA expression in either PBMCs or AMs.
Similarly, TB did not influence mRNA levels of A20 or
SIGIRR in PBMCs or AMs. A possible role for A20 in
TB pathogenesis has not been investigated thus far,
although its central role as an inducible inhibitor of NF-
κB activation suggests A20 may be important [46]. Con-
sistent with the TLR inhibiting role of SIGIRR, SIGIRR
deficient mice showed exaggerated inflammation and in-
creased lethality after infection with Mtb despite an effi-
cient control of mycobacterial growth [47].Conclusions
Innate immunity needs to be controlled carefully in
order to prevent damage to cells and tissues due to aber-
rant inflammation. The immune system harbors a large
variety of negative regulators that upon interaction be-
tween immune cells and pathogens become activated in
parallel with immune enhancers. While previous studies
examined the expression of immune enhancers, and in
particular TLRs, during TB [8-11], we here report on an
expression of a group of inhibitory regulators of innate
immunity, differential expression of these “immune con-
trollers” in PBMCs of patients with active TB relative to
healthy blood donors. As such, our study provides evi-
dence that in patients with TB activation of innate im-
munity is kept in check by several negative regulators.
Furthermore, in patients elevated sST2 plasma levels
correlated with several established TB biomarkers, sug-
gesting that sST2 could be a useful marker for TB dis-
ease activity and treatment response.Abbreviations
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